TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03892564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 Cream, irradiation
Description: One application of MC2-01 Cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 Cream, no irradiation
Description: One application of MC2-01 Cream. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 vehicle, irradiation
Description: One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 vehicle, no irradiation
Description: One application of MC2-01 vehicle. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control, irradiation
Description: Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Study: NCT02079844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Roflumilast placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Roflumilast placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Roflumilast placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second generation antipsychotic
Description: Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second generation antipsychotic
Description: Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second generation antipsychotic
Description: Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.
Study: NCT02740400

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-GS
Description: The equipment for EBUS-GS includes super-thin bronchoscope BF-P260F, endobronchial ultrasonic system EU-M30S, ultrasonic probe UM-S20-17S, and guided sheath kit K201. All facilities are provided by Olympus Co. The EBUS-GS procedure was performed by thoracic surgeons. The patient was in supine position, under general anesthesia, and provided ventilatation through laryngeal mask. First, the operator placed super-thin bronchoscope into the bronchus of interest, inserted the probe covered with GS through a work channel. Later, adjusted the bronchoscope and probe to obtain classical ultrasonic graphs. The assistant fixed the bronchoscope, pulled the probe out, and placed the brush and biopsy forceps, respectively, through the GS. This process was assisted using x-ray fluoroscope or not.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-TTNB
Description: The devices for CT-TTNB includes Lightspeed VCT spiral CT(GE co.) and Quickcore(COOK Co.) biopsy kit. The kit includes a sheath(5cm in length and 16G in outer diameter) and a automatic biopsy needle(15cm in length and 18G in outer diameter). The patient stays in supine, prone or lateral position according to the lesion's location. The first chest CT scan is performed to confirm the location of the lesion and make an optimal entry point. Then, after sterilization and 2% lidocaine local anesthesia, the sheath is stabbed into chest wall through the entry point. The second CT scan is performed to make sure that the sheath stays in proper angle and depth. The operator places the needle through the sheath and enter the lesion. Then fire the biopsy needle and repeat the procedure twice or third time. The last CT scan is conducted to determine whether pneumothorax or hemorrhage occurred.
Study: NCT03855007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX，7.5mg to 15mg, po, once per week (Qw) prescribed if needed and adjusted due to patient response or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: HCQ，200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pred
Description: Pred, 5-15mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
Study: NCT03489187

Intervention type: DEVICE
Intervention: Visualase Thermal Therapy System
Description: Patients who have previously received treatment with VTTS when used as intended.
Study: NCT01298934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
Study: NCT00750620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral
Study: NCT01957124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF (Platelet-Rich Fibrin)
Study: NCT03082924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calibrated cycle ergometer and threshold loading device
Description: Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
Study: NCT01905540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184AQ
Description: Magnesium salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184AQ
Description: Magnesium salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184SS
Description: Disodium salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184SS
Description: Disodium salt
Study: NCT02283034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CPRmeter
Description: Feedback device - 1
Study: NCT01029587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab will be administered by intravenous infusion. Eculizumab will be administered at a dose of 1200mg by intravenous (IV) infusion on the day of or on the day prior to kidney transplantation, and at a dose of 900mg IV on post-operative day 1. Subsequently, the post-operative dosing regimen would be comprised of an induction phase of weekly doses of 900mg IV per dose followed by a maintenance phase of every other week dosing of 1200mg IV per dose. The weekly induction dosing regimen would begin on postoperative day 8, and would continue for three doses (specifically, doses of 900mg IV would be given on postoperative days 8, 15, and 22). The maintenance phase of dosing would begin with a dose of 1200mg on postoperative day 29, and would continue for a total of 5 doses (specifically, doses of 1200mg IV would be given on postoperative days 29, 43, 47, 72, and 85). In most cases, eculizumab would be discontinued after the 5th maintenance dose.
Study: NCT03133234

Intervention type: DRUG
Intervention: osimertinib
Description: Oral dose of 80mg once daily
Study: NCT01608347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMWH+Folic acid
Description: Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
Study: NCT02283034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The PocketCPR
Description: Feedback device - 2
Study: NCT03060083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduce cigarettes per day (CPD) with nicotine replacement therapy (NRT)
Description: Participants will reduce cigarettes per day (CPD) with the aid of nicotine replacement therapy (NRT)
Study: NCT01616888

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA with drug eluting balloon with paclitaxel
Description: Angioplasty with drug eluting balloon with paclitaxel on femoropopliteal arteries
Study: NCT04410198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arm description.
Study: NCT00507416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib bolus intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib bolus intravenous (IV) injection
Study: NCT02515305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin and Benzoyl Peroxide Gel (combination)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel (combination)
Study: NCT00903162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide
Description: Given intramuscularly beginning on day 1 and then either 7.5 mg every month or 22.5 mg every 3 months for two years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Taken orally once a day 6-8 weeks after initial leuprolide administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: If desired, given intravenously every 6 months for a total of 4 injections (optional)
Study: NCT03310866

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic, airway
Description: classic fiberoptic bronchoscope, fenstrated airway

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiberoptic, Machintosh
Description: oral fiberoptic brochoscopic, Machintosh laryngoscope
Study: NCT00507416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib bolus intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide for oral administration
Study: NCT00883220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management of urinary catheter
Description: Awareness, self-monitoring, and self-management of urine flow are taught. Focus is on attaining adequate and consistent levels of fluid intake and preventing catheter dislodgement.
Study: NCT03209440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity Therapy - Nurse Led
Description: The nurse-led intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Palliative care nurses usually see patients each clinic visit to assess vital signs, function, symptoms, and to provide patient and family education. They document findings and interventions in the electronic health record (EHR). Whereas usual care for palliative care chaplaincy in the outpatient setting varies by site, chaplaincy care for usual care patients in this study will follow the usual practice for inpatient palliative care chaplaincy, which is to visit all new referrals to the clinic and assess their spiritual and religious needs. This assessment is then memorialized in a spiritual treatment plan documented in the EHR.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity Therapy - Chaplain Led
Description: The chaplain-led DT intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
Study: NCT03848611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 plus JS001
Description: CM082：150mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
Study: NCT04273126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Family Resilience Intervention
Description: The program consists of approximately 8-10 modules lasting approximately one hour. Sessions focus on psychoeducation and key resilience skills.
Study: NCT01740388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifloxacin
Description: one drop of besifloxacin ophthalmic suspension 0.6% administered to infected study eye(s) BID for 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: one drop of the vehicle of besifloxacin ophthalmic suspension administered to infected study eye(s) BID for 3 days.
Study: NCT03878199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic SCT
Study: NCT02769806

Intervention type: PROCEDURE
Intervention: MRI
Study: NCT03878199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study: NCT03421678

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Sample
Description: One to two home visits where tobacco use and medical history and biological samples will be collected including blood, buccal cells and urine

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Sample
Description: One to two home visits where tobacco use and medical history and biological samples will be collected including blood, buccal cells and urine

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Sample
Description: One to two home visits where tobacco use and medical history and biological samples will be collected including blood, buccal cells and urine
Study: NCT02436317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point Of Care Ultrasound
Description: Examination with an ultrasound machine
Study: NCT04144595

Intervention type: DIAGNOSTIC_TEST
Intervention: 2 hour 75 g Oral glucose tolerance test
Description: In pregnant women between 24 and 34 weeks of gestational age, plasma glucose was recorded after an overnight fast. Following consumption of 75 g glucose in 200 mL water over 10 min, the equivalent 1 hour and 2 hour values was recorded
Study: NCT03814330

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sedation/Analgesia
Description: Patients will be performed the procedure with sedation/analgesia under the condition of spontaneous breathing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway
Description: Patients will be performed the procedure with Laryngeal Mask Airway during the procedure. Laryngeal Mask Airway is a supraglottic airway device to ventilate the patients during anesthetic procedure.
Study: NCT02629913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mementor somnium

Intervention type: OTHER
Group type: OTHER
Intervention: wait list
Description: delayed access to mementor somnium
Study: NCT02989168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: GBT440: Capsules which contain GBT440 drug substance in Swedish orange

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: GBT440: Capsules which contain GBT440 drug substance in Swedish orange
Study: NCT02914236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivaer Stylus
Description: Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
Study: NCT01031966

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MF59 adjuvanted H1N1 influenza monovalent vaccine
Description: One/two single administration
Study: NCT03242005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed® Pro-set®
Description: Utilization of the MiniMed® Pro-set® to administer the subject's current insulin therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed® Quick-set®
Description: Utilization of the MiniMed® Quick-set® to administer the subject's current insulin therapy.
Study: NCT01995279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: French ear acupuncture
Description: Single session (20 minutes) of French ear acupuncture at specific location used to reduce low back pain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Ultrasound
Description: Ultrasound turned off.
Study: NCT01031966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Description: 1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Description: 1.6 mg, 6.4 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
Study: NCT04415736

Intervention type: OTHER
Intervention: No intervention, observational study

Intervention type: OTHER
Intervention: No intervention, observational study
Study: NCT03829137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum laser acupuncture
Description: The patients lay in the supine position before treatment and the gallium aluminum arsenide LaserPan (RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany) will be applied to each selected acupoints for 3 weeks, total of 9 sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture
Description: The acupuncture points and procedure of the control group are identical to the experimental group but there are no laser beam energy.
Study: NCT01996605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin 15 mcg
Description: Oxytocin 15 mcg will be administered spinally
Study: NCT00816361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
Study: NCT03149458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dance
Description: dance program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: upper limb rehabilitation
Study: NCT00629265

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)
Description: NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
Study: NCT01996605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin 150 mcg
Description: Oxytocin 150 mcg will be administered spinally
Study: NCT00629265

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)
Description: NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
Study: NCT01659736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.